VRTX · News · 20261104N
Guidance / Outlook
VERTEX PHARMACEUTICALS INC / MA · 2026-11-04 · Importance 62 · Surprise 60 · In source text
Vertex raised its full-year revenue guidance to a top end of $13.25 billion. The report identified Q3 2026 revenue of $3.44 billion, up 12% year over year, as the reported quarterly performance accompanying the guidance increase. It also reported adjusted operating income of $1.41 billion, up 2%, and non-GAAP earnings per share of $4.76, down 0.8%.
Key facts
- Vertex raised its full-year revenue guidance to a top end of $13.25 billion. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | committed | — | Vertex raised its full-year revenue guidance to a top end of $13.25 billion. |